Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 296

1.

SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents a therapeutic target with high potential.

Tian YF, Chen TJ, Lin CY, Chen LT, Lin LC, Hsing CH, Lee SW, Sheu MJ, Lee HH, Shiue YL, Huang HY, Pan HY, Li CF, Chen SH.

Tumour Biol. 2013 Apr;34(2):1107-17. doi: 10.1007/s13277-013-0652-z.

PMID:
23328995
2.

Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation.

Lin CY, Tian YF, Wu LC, Chen LT, Lin LC, Hsing CH, Lee SW, Sheu MJ, Lee HH, Wang YH, Shiue YL, Wu WR, Huang HY, Hsu HP, Li CF, Chen SH.

J Clin Pathol. 2012 Aug;65(8):687-92. doi: 10.1136/jclinpath-2012-200786.

PMID:
22569540
3.

Overexpression of CPS1 is an independent negative prognosticator in rectal cancers receiving concurrent chemoradiotherapy.

Lee YY, Li CF, Lin CY, Lee SW, Sheu MJ, Lin LC, Chen TJ, Wu TF, Hsing CH.

Tumour Biol. 2014 Nov;35(11):11097-105. doi: 10.1007/s13277-014-2425-8.

PMID:
25099619
4.

Clinical significance of pre- to post-chemoradiotherapy s-CEA reduction ratio in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection.

Kim CW, Yu CS, Yang SS, Kim KH, Yoon YS, Yoon SN, Lim SB, Kim JC.

Ann Surg Oncol. 2011 Nov;18(12):3271-7. doi: 10.1245/s10434-011-1740-1.

PMID:
21537868
5.

Prognostic significance of glucose transporter-1 (GLUT1) gene expression in rectal cancer after preoperative chemoradiotherapy.

Saigusa S, Toiyama Y, Tanaka K, Okugawa Y, Fujikawa H, Matsushita K, Uchida K, Inoue Y, Kusunoki M.

Surg Today. 2012 May;42(5):460-9. doi: 10.1007/s00595-011-0027-2.

PMID:
22072148
6.

Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.

Shanmugan S, Arrangoiz R, Nitzkorski JR, Yu JQ, Li T, Cooper H, Konski A, Farma JM, Sigurdson ER.

Ann Surg Oncol. 2012 Jul;19(7):2178-85. doi: 10.1245/s10434-012-2248-z.

PMID:
22395978
7.

Phosphatidylinositol 3-kinase CB association with preoperative radiotherapy response in rectal adenocarcinoma.

Yu WD, Peng YF, Pan HD, Wang L, Li K, Gu J.

World J Gastroenterol. 2014 Nov 21;20(43):16258-67. doi: 10.3748/wjg.v20.i43.16258.

8.

p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy.

Saw RP, Morgan M, Koorey D, Painter D, Findlay M, Stevens G, Clarke S, Chapuis P, Solomon MJ.

Dis Colon Rectum. 2003 Feb;46(2):192-202.

PMID:
12576893
9.

Preoperative chemoradiotherapy improves local recurrence free survival in locally advanced rectal cancer.

Tural D, Ozturk M, Selcukbiricik F, Yildiz O, Elicin O, Turna H, Guney S, Ozguroglu M.

J BUON. 2013 Apr-Jun;18(2):385-90.

PMID:
23818350
10.
11.

Impact of perineural and lymphovascular invasion on oncological outcomes in rectal cancer treated with neoadjuvant chemoradiotherapy and surgery.

Cienfuegos JA, Rotellar F, Baixauli J, Beorlegui C, Sola JJ, Arbea L, Pastor C, Arredondo J, Hernández-Lizoáin JL.

Ann Surg Oncol. 2015 Mar;22(3):916-23. doi: 10.1245/s10434-014-4051-5.

PMID:
25190129
12.

Long-term outcome of patients with complete pathologic response after neoadjuvant chemoradiation for cT3 rectal cancer: implications for local excision surgical strategies.

Belluco C, De Paoli A, Canzonieri V, Sigon R, Fornasarig M, Buonadonna A, Boz G, Innocente R, Perin T, Cossaro M, Polesel J, De Marchi F.

Ann Surg Oncol. 2011 Dec;18(13):3686-93. doi: 10.1245/s10434-011-1822-0.

13.

Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer.

Uddin S, Ahmed M, Bavi P, El-Sayed R, Al-Sanea N, AbdulJabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Hussain AR, Al-Kuraya KS.

Cancer Res. 2008 May 1;68(9):3379-88. doi: 10.1158/0008-5472.CAN-07-6109.

14.

Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy.

Arredondo J, Baixauli J, Beorlegui C, Arbea L, Rodríguez J, Sola JJ, Chopitea A, Hernández-Lizoáin JL.

Dis Colon Rectum. 2013 Apr;56(4):416-21. doi: 10.1097/DCR.0b013e318274d9c6.

PMID:
23478608
15.

Improved outcomes for rectal cancer in the era of preoperative chemoradiation and tailored mesorectal excision: a series of 338 consecutive cases.

Pacelli F, Sanchez AM, Covino M, Tortorelli AP, Bossola M, Valentini V, Gambacorta MA, Doglietto GB.

Am Surg. 2013 Feb;79(2):151-61.

PMID:
23336654
16.

Fibroblast growth factor receptor 2 overexpression is predictive of poor prognosis in rectal cancer patients receiving neoadjuvant chemoradiotherapy.

Li CF, He HL, Wang JY, Huang HY, Wu TF, Hsing CH, Lee SW, Lee HH, Fang JL, Huang WT, Chen SH.

J Clin Pathol. 2014 Dec;67(12):1056-61. doi: 10.1136/jclinpath-2014-202551.

PMID:
25271212
17.

Thymidylate synthase as a prognostic biomarker for locally advanced rectal cancer after multimodal treatment.

Conradi LC, Bleckmann A, Schirmer M, Sprenger T, Jo P, Homayounfar K, Wolff HA, Rothe H, Middel P, Becker H, Ghadimi MB, Beissbarth T, Liersch T.

Ann Surg Oncol. 2011 Sep;18(9):2442-52. doi: 10.1245/s10434-011-1608-4.

18.

Effect of long interval between hyperthermochemoradiation therapy and surgery for rectal cancer on apoptosis, proliferation and tumor response.

Kato T, Fujii T, Ide M, Takada T, Sutoh T, Morita H, Yajima R, Yamaguchi S, Tsutsumi S, Asao T, Oyama T, Kuwano H.

Anticancer Res. 2014 Jun;34(6):3141-6.

PMID:
24922685
19.

Prognostic value of Smac expression in rectal cancer patients treated with neoadjuvant therapy.

Yan H, Yu J, Wang R, Jiang S, Zhu K, Mu D, Xu Z.

Med Oncol. 2012 Mar;29(1):168-73. doi: 10.1007/s12032-011-9819-x.

PMID:
21264534
20.

Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.

Liersch T, Langer C, Ghadimi BM, Kulle B, Aust DE, Baretton GB, Schwabe W, Häusler P, Becker H, Jakob C.

J Clin Oncol. 2006 Sep 1;24(25):4062-8.

PMID:
16943523
Items per page

Supplemental Content

Support Center